ADMS insider filings
Adamas Pharmaceuticals Inc — 34 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-11-24. Screen ADMS transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for ADMS between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Adamas Pharmaceuticals Inc
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2021-11-24 | 4 | McFarlane Neil F. — Chief Executive Officer, Director | Grant/award (A): 75,000 @ $0 · Code (U): 600,000 · Disposition to issuer (D): 250,000 (derivative) · Disposition to issuer (D): 200,000 (derivative) | EDGAR |
| 2021-11-24 | 4 | Prentiss Christopher B — Chief Financial Officer | Grant/award (A): 18,750 @ $0 · Code (U): 163,767 · Disposition to issuer (D): 37,500 (derivative) · Disposition to issuer (D): 50,000 (derivative) | EDGAR |
| 2021-11-24 | 4 | Ericson William W. — Director, 10% owner | Code (U): 10,000 · Code (U): 4,031,804 · Code (U): 6,043 · Code (U): 3,146 · Code (U): 25,661 · Code (U): 287,992 · +4 more | EDGAR |
| 2021-11-24 | 4 | Shreedhar Vijay — Chief Commercial Officer | Grant/award (A): 18,750 @ $0 · Code (U): 186,786 · Disposition to issuer (D): 137,500 (derivative) · Disposition to issuer (D): 47,500 (derivative) | EDGAR |
| 2021-11-24 | 4 | Papapetropoulos Spyridon — Director | Code (U): 20,975 · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) | EDGAR |
| 2021-11-24 | 4 | MacPhee John A — Director | Code (U): 202,000 · Disposition to issuer (D): 24,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) | EDGAR |
| 2021-11-24 | 4 | MAHONEY DAVID L — Director | Code (U): 5,000 · Code (U): 112,781 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 40,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) | EDGAR |
| 2021-11-24 | 4 | BIGHAM MICHAEL — Director | Code (U): 10,000 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) | EDGAR |
| 2021-11-24 | 4 | RICHO ANNA — Director | Code (U): 25,000 · Disposition to issuer (D): 20,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) | EDGAR |
| 2021-11-24 | 4 | DEMSKI MARTHA J — Director | Code (U): 16,000 · Code (U): 5,000 · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) | EDGAR |
| 2021-06-23 | 4 | Shreedhar Vijay — Chief Commercial Officer | Sale (S): 6,200 @ $5.16 | EDGAR |
| 2021-06-08 | 4 | DEMSKI MARTHA J — Director | Sale (S): 2,000 @ $5.17 | EDGAR |
| 2021-06-04 | 4 | Papapetropoulos Spyridon — Director | Grant/award (A): 5,000 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | MacPhee John A — Director | Grant/award (A): 5,000 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Ericson William W. — Director, 10% owner | Grant/award (A): 5,000 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Dier Mardi — Director | Grant/award (A): 5,000 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | MAHONEY DAVID L — Director | Grant/award (A): 5,000 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | BIGHAM MICHAEL — Director | Grant/award (A): 5,000 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | RICHO ANNA — Director | Grant/award (A): 5,000 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | DEMSKI MARTHA J — Director | Grant/award (A): 5,000 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2021-03-23 | 4 | Shreedhar Vijay — Chief Commercial Officer | Sale (S): 1,051 @ $5.50 | EDGAR |
| 2021-03-23 | 4 | Prentiss Christopher B — Chief Financial Officer | Sale (S): 2,422 @ $5.48 | EDGAR |
| 2021-03-16 | 4 | MacPhee John A — Director | Option exercise (M): 192,000 @ $0.67 · Option exercise (M): 192,000 (derivative) @ $0 | EDGAR |
| 2021-03-16 | 4 | MAHONEY DAVID L — Director | Option exercise (M): 48,000 @ $0.67 · Option exercise (M): 48,000 (derivative) @ $0 | EDGAR |
| 2021-03-15 | 4 | Papapetropoulos Spyridon — Director | Purchase (P): 5,975 @ $5.06 | EDGAR |
| 2021-03-03 | 4 | McFarlane Neil F. — Chief Executive Officer | Grant/award (A): 300,000 @ $0 | EDGAR |
| 2021-03-03 | 4 | Shreedhar Vijay — Chief Commercial Officer | Grant/award (A): 75,000 @ $0 | EDGAR |
| 2021-03-03 | 4 | Prentiss Christopher B — Chief Financial Officer | Grant/award (A): 75,000 @ $0 | EDGAR |
| 2021-02-01 | 4 | Prentiss Christopher B — Chief Financial Officer | Sale (S): 3,821 @ $6.36 | EDGAR |
| 2021-02-01 | 4 | Shreedhar Vijay — Chief Commercial Officer | Sale (S): 4,514 @ $6.39 | EDGAR |
| 2021-01-22 | 4 | Prentiss Christopher B — Chief Financial Officer | Sale (S): 2,630 @ $4.41 | EDGAR |
| 2020-11-24 | 4 | Papapetropoulos Spyridon — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2020-11-02 | 4 | Prentiss Christopher B — Chief Financial Officer | Sale (S): 2,050 @ $3.21 | EDGAR |
| 2020-09-01 | 4 | RICHO ANNA — Director | Grant/award (A): 10,000 @ $0 · Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Adamas Pharmaceuticals Inc
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2021-11-24 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-10-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-08-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-06-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2021-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2021-05-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-02-25 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-02-23 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2021-02-01 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2021-01-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ADMS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs